Evidence map›Paper›PMID 39027809›Full record

ArticleJournal of clinical medicine research2024

Mapping the Grounds for Mortalities in Acute Myeloid Leukemia Through Registry Analyses: A Retrospective Cohort Study of Children, Adolescents, and Young Adults Patients.

Anas Elgenidy, Mohammed Al-Mahdi Al-Kurdi, Hoda Atef Abdelsattar Ibrahim, Eman F Gad, Ahmed K Awad, Rebecca Caruana, Sheriseane Diacono, Aya Sherif, Tasneem Elattar, Islam E Al-Ghanam and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Anas ElgenidyFaculty of Medicine, Cairo University, Cairo, Egypt.
Mohammed Al-Mahdi Al-KurdiFaculty of Medicine, University of Aleppo, Aleppo, Syrian Arab Republic.
Hoda Atef Abdelsattar IbrahimDepartment of Pediatrics, Faculty of Medicine, Cairo University, Cairo 12613, Egypt.ORCID https://orcid.org/0000-0001-5399-8861
Eman F GadDepartment of Pediatrics, Assiut University, Assiut 71516, Egypt.
Ahmed K AwadFaculty of Medicine Ain-Shams University, Cairo, Egypt.
Rebecca CaruanaMater dei Hospital, Msida, Malta.
Sheriseane DiaconoMater dei Hospital, Msida, Malta.
Aya SherifFaculty of Medicine, Beni Suef University, Beni Suef, Egypt.
Tasneem ElattarFaculty of Clinical Pharmacy, Al Azhar University, Cairo, Egypt.
Islam E Al-GhanamFaculty of Medicine Ain-Shams University, Cairo, Egypt.
Asmaa M EldmatyFaculty of Medicine, Cairo University, Cairo, Egypt.
Tareq M AbubasheerFaculty of Medicine, Al-Quds University, Palestine.
Ahmed M AfifiDepartment of Surgery, University of Toledo Medical Center, Toledo, OH, USA.
Amira ElhoufeyDepartment of Community Health Nursing, Alddrab University College, Jazan University, Jazan 45142, Saudi Arabia.
Hamad Ghaleb DailahResearch and Scientific Studies Unit, College of Nursing, Jazan University, Jazan, Saudi Arabia.
Amira M OsmanDepartment of Pediatric Oncology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
Mohamed EzzatDepartment of Pediatrics, Faculty of Medicine, Al Azhar University, Cairo, Egypt.
Doaa Ali GamalDepartment of Clinical Oncology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Rady ElmonierDepartment of Internal Medicine, Faculty of Medicine, Al-Azhar University, New Damietta, Egypt.
Ahmed El-Sayed HammourDepartment of Pediatrics, Faculty of Medicine, Al Azhar University, Cairo, Egypt.
Maged T AbougabalDepartment of Pediatrics, Zagazig University, Zagazig, Egypt.
Khaled SaadDepartment of Pediatrics, Assiut University, Assiut 71516, Egypt.ORCID https://orcid.org/0000-0002-8473-6116

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Our objective was to identify non-malignant factors that contribute to mortality in children, adolescents and young adults, aiming to improve patient follow-up and reduce mortality rates to achieve better survival outcomes. Methods: We analyzed 8,239 acute myeloid leukemia (AML) cases diagnosed between 2000 and 2019 in the USA. Using version 8.4.0.1 of the Surveillance, Epidemiology, and End Results (SEER)*Stat software, we calculated the standardized mortality ratios (SMRs) and 95% confidence intervals (CIs) for each cause of death. Results: Out of the 3,165 deaths observed in the study population, the majority (2,245;70.9%) were attributed to AML itself, followed by non-AML cancers (573; 18.1%) and non-cancerous causes (347; 10.9%). Conclusions: Patients with AML are at a higher risk of developing other types of cancer and granulocyte deficiencies, which increases the risk of death from non-cancerous causes such as infections. Moreover, treatment for AML carries the risk of cardiac problems. AML is commoner in males than females.

Indexed as

Acute myeloid leukemiaChildrenNon-cancerous mortality causeSEER databaseStandardized mortality ratios

Identifiers

PMID39027809
PMCPMC11254311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.